CASI Pharmaceuticals (NASDAQ:CASI) versus Surface Oncology (NASDAQ:SURF) Head-To-Head Analysis

Surface Oncology (NASDAQ:SURF) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Valuation and Earnings

This table compares Surface Oncology and CASI Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Surface Oncology $59.42 million 1.29 -$6.60 million ($0.33) -8.33
CASI Pharmaceuticals N/A N/A -$27.47 million ($0.32) -9.34

Surface Oncology has higher revenue and earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Surface Oncology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Surface Oncology and CASI Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Surface Oncology -148.15% -38.97% -22.92%
CASI Pharmaceuticals N/A -31.22% -28.32%

Analyst Recommendations

This is a summary of current recommendations and price targets for Surface Oncology and CASI Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Surface Oncology 0 0 2 0 3.00
CASI Pharmaceuticals 0 0 1 0 3.00

Surface Oncology presently has a consensus target price of $23.00, suggesting a potential upside of 736.36%. CASI Pharmaceuticals has a consensus target price of $7.00, suggesting a potential upside of 134.11%. Given Surface Oncology’s higher possible upside, analysts clearly believe Surface Oncology is more favorable than CASI Pharmaceuticals.

Volatility & Risk

Surface Oncology has a beta of 3.03, suggesting that its stock price is 203% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.

Insider and Institutional Ownership

59.0% of Surface Oncology shares are held by institutional investors. Comparatively, 12.0% of CASI Pharmaceuticals shares are held by institutional investors. 33.0% of Surface Oncology shares are held by insiders. Comparatively, 24.3% of CASI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Surface Oncology beats CASI Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Surface Oncology Company Profile

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkin's lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. In addition, the company engages in the development of a portfolio of 26 FDA-approved abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate indicated for hepatitis B virus; and 4 pipeline ANDAs that are pending FDA approval. Further, it is involved in developing ENMD-2076, an Aurora A/angiogenic kinase inhibitor that has completed Phase II studies for solid tumors, as well as various proprietary early-stage immune-oncological potential candidates in preclinical development. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.